
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.

Professor Celeste Porsbjerg presents the pathophysiology and disease processes involved in airway remodeling in severe asthma.

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.

Prof. Mullol share his opinion on connection between loss of smell and sleep disorder in patients with CRSwNP.

Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP
Professor Enno Schmidt discusses the pathophysiology of BP, focusing on the role of type 2 inflammation and blister formation

Exploring the role of type 2 inflammation and the neuroimmune axis in CSU, and how emerging therapeutics are targeting key molecules in these pathways.

Dr. Jason Hawkes details the role of IL-4 and IL-13 in the pathophysiology of CSU at EADV 2025
Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.